Aim: To verify the suppressive effect of berberine on the proliferation of the human pulmonary giant cell carcinoma cell line PG and to demonstrate the mechanisms behind the antitumoral effects of berberine. Methods: The proliferative effects of PG cells were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide colorimetry. The cell cycle was examined by flow cytometry. The expression level of cyclin D1 was detected by RT-PCR. The activities of the activating protein-1 (AP-1) and NF-κB signaling pathways related to cyclin D1 were examined by luciferase assay. The cytoplasmic level of c-Jun was detected by Western blot analysis. An electrophoretic mobility shift assay was used to examine the binding of transcription factors to the cyclin D1 gene (CCND1) AP-1 motif. Results: The results showed that the proliferation of PG cells treated with different concentrations (10, 20, and 40 µg/mL) of berberine for 24 and 48 h was suppressed significantly compared to the control group. After treatment with berberine, the proportion of PG cells at the G 0 /G 1 phase increased, while cells at the S and G 2 /M phases decreased. Berberine could inhibit the expression of cyclin D1 in PG cells. Berberine inhibited the activity of the AP-1 signaling pathway, but had no significant effect on the NF-κB signaling pathway. Berberine suppressed the expression of c-Jun and decreased the binding of transcription factors to the CCND1 AP-1 motif. Conclusion: Berberine suppresses the activity of the AP-1 signaling pathway and decreases the binding of transcription factors to the CCND1 AP-1 motif. This is one of the important mechanisms behind the antitumoral effects of berberine as a regulator of cyclin D1.
Introduction
Berberine is an isoquinoline derivative alkaloid isolated from many medicinal herbs, such as Rhizoma coptidis and Cortex phellodendri. It is widely used in traditional Chinese medicine for antimicrobial and anti-inflammatory activities. In recent years, berberine has been reported to have a wide range of pharmacological effects, including immunological regulation [1] , myocardial protection [2] , inhibition of tumor cell proliferation [3] , and invasion [4] . Recently, we reported the inhibitory effect of berberine on the invasion and migration of lung carcinoma cells [5] . Cyclin D1 is a member of the G 1 cyclin family involved in the regulation of the G 1 /S transition of the cell cycle [6] . The cyclin D1/cyclin-dependent kinase 4 (CDK4) complex can hyperphosphorylate retinoblastoma tumor suppressor protein 1 (Rb1) [7] , leading to the dissociation of E2 promoter-binding protein dimerization partners (E2F) from the Rb1/E2F complex [8] . Dissociated E2F induces the transcription of cyclin E and other genes required for entry into the S phase. Cyclin D1 is frequently overexpressed in a wide range of cancers. The nuclear accumulation of cyclin D1 induces uncontrolled proliferation in normal human cells, which may facilitate the development of invasive cancer [9] . The cyclin D1 expression is under complex regulation and is markedly influenced by the activating protein-1 (AP-1), NF-κB, and β-catenin/T cell factor (TCF) signaling pathways [10] [11] [12] . A number of compounds targeting these signaling pathways can indirectly attenuate the cyclin D1 expression to mediate cell cycle arrest.
AP-1 is a sequence-specific transcription factor composed of homodimers or heterodimers of the Jun family (cJun, Jun D, and Jun B) or heterodimers of the Jun family members with any of the Fos family members (c-Fos, Fos B, Fra1, and Fra2). AP-1 has long been associated with proliferation. AP-1 directs the expression of a critical target gene or genes, such as the cyclin D1 gene, in response to cytokines, stress, and mitogenic signals [13] . The promoter for CCND1 (encoding cyclin D1) contains an AP-1 motif, and the ectopic expression of c-Jun induces the cyclin D1 mRNA expression [14] . The present study was performed to verify the suppressive effect of berberine on the proliferation of the human pulmonary giant cell carcinoma cell line PG and demonstrate the mechanisms behind the antitumoral effects of berberine.
Materials and methods
Cell culture Human pulmonary giant cell carcinoma cell line PG (Peking University Medical Center, Beijing, China) [15] were cultivated in RPMI-1640 medium supplemented with 10% fetal bovine serum. Cell cultures were maintained in a 37 °C incubator under a humidified 5% CO 2 atmosphere, and were routinely subcultured by trypsinization. All experiments were performed on logarithmically-growing cells.
Cell proliferation/viability assay The PG cells were seeded onto 96-well culture plates and incubated for 24 h at 37 °C and then treated with berberine (10, 20, and 40 µg/mL; NICPBP, Beijing, China) or without. After 24 or 48 h, cell proliferation was assayed by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) kit (Promega, Madison, WI, USA). The absorbance was recorded with a microplate reader (model 550, Bio-Rad, Hercules, CA, USA); viability was determined as (%)=(A 570 -A 630 ) sample/(A 570 -A 630 ) control×100%.
Cell cycle analysis The PG cells were treated with berberine (0, 20, and 40 µg/mL) for 48 h. The cells were then harvested, washed with cold phosphate-buffered saline (PBS), and processed for cell cycle analysis. Briefly, 2×10 5 cells were resuspended in 0.5 mL cold PBS, to which cold ethanol (70%, 5 mL) was added; the cells were then incubated for 1 h at 4 °C. After centrifugation, the pellet was washed with cold PBS, suspended in 0.3 mL PBS, and incubated with 50 µL RNase (1 mg/mL) for 30 min at 37 °C. The cells were kept on ice for 10 min and incubated with 500 µL propidium iodide (50 mg/L) for 30 min in the dark. The cell cycle distribution of the cells of each sample was then determined by using a FACSCalibur instrument (BD Biosciences, San Jose, CA, USA) equipped with FACSort Cell Quest software. Cell transfection and luciferase assay The PG cells were seeded onto 96-well plates and incubated for 24 h at 37 °C. For each well, 100 ng pAP-1-Luc (or pNF-κB-Luc) and 10 ng pRL-TK (Promega, USA) were mixed and cotransfected using the calcium phosphate precipitation method according to standard protocols [16] . The cells were treated with the indicated concentrations of berberine for 6 h after transfection, and incubated for an additional 24 h. The stimulus group was treated with phorbol myristate acetate (PMA and ionomycin (P+I) for 6 h before being lysed. The cells were then lysed in 40 µL of passive lysis buffer (Promega, USA). Firefly luciferase and Renilla luciferase activities were measured with 10 µL cell lysate using the Dual luciferase reporter assay system (Promega, USA) in a GENios pro reader (Tecan, Hombrechtikon, Switzerland). Relative activity was defined as the ratio of firefly luciferase activity to Renilla luciferase activity and was calculated by dividing the luminescence intensity obtained in the assay for firefly luciferase by that obtained for Renilla luciferase.
RT-PCR
Western blot analysis After the berberine treatments, the PG cells were harvested, and whole-cell lysates were prepared. Equal amounts of protein samples were separated by SDS-PAGE gel and blotted onto nitrocellulose (NC) membrane (Millipore, Bedford, MA, USA). After blocking, the membranes were incubated at 4 °C with antibodies against cJun (1:500) or cyclin D1 (1:200; Santa Cruz Biotechnologies, Santa Cruz, CA, USA). β-Actin was used as an internal loading control. The blots were then washed and incubated for 1 h with horseradish peroxidase-labeled secondary antibody (1:4000; Zhongshan Golden Bridge, Beijing, China). Immunoreactive bands were visualized with a SuperSignal West Pico chemiluminescnet kit (Pierce, Rockford, IL, USA).
Electrophoretic mobility shift assay Nuclear extracts were prepared by using a NE-PER nuclear and cytoplasmic extrac-tion reagent kit (Pierce, USA) according to standard protocols. The CCND1 AP-1 site, the wild-type collagenase AP-1 site, and a mutant CCND1 AP-1 site were synthesized as complementary oligodeoxyribonucleotide strands. The sequence of the CCND1 promoter AP-1 site oligodeoxyribonucleotides was 5´-TCC ATT CTG ACT CAT TTT TTT TAA-3´, and the sequence of the mutant AP-1 site was 5´-TCC ATT CTG cCg CAT TTT TTT TAA-3´. The sequence of the wild-type collagenase AP-1 oligodeoxyribonucleotides was 5´-CGC TTG ATG AGT CAG CCG GAA-3´ [ 17] . The DNA binding ability of AP-1 in the nuclear extracts was assessed by electrophoretic mobility shift assay (EMSA) [18] with biotin-labeled, double-stranded, wild-type collagenase AP-1 oligonucleotides and CCND1 AP-1 oligonucleotides. EMSA was carried out by using the Lightshift chemiluminescent EMSA kit (Pierce, USA). Specific binding was confirmed by using a 250-fold excess of an unlabeled probe as a specific competitor. Protein-DNA complexes were separated by using a 6% non-denaturing acrylamide gel electrophoresis and then transferred to positively-charged nylon membranes and cross-linked by UV irradiation. Gel shifts were visualized with streptavidin horseradish peroxidase according to standard protocols.
Statistical analysis All data are expressed as mean±SD. Student's unpaired t-test was used to compare differences between 2 groups. Figures were obtained from at least 3 independent experiments with similar patterns.
Results
Berberine inhibits the proliferation and viability of PG cells The PG cells were treated with 0, 10, 20, and 40 µg/mL berberine for 24 and 48 h. The treatment of the PG cells with berberine (10-40 µg/mL) resulted in a significant reduction in cell proliferation/viability as assessed by MTT assay, ranging from 27% to 36% (P<0.01) after 24 h, and 63% to 73% (P<0.01) after 48 h ( Figure 1A ). Berberine induces G 1 phase cell cycle arrest in PG cells As we found a significant growth inhibitory effect of berberine on PG cells, we determined the possible inhibitory effect of berberine on cell cycle progression. The treatment of PG cells with berberine (20 and 40 µg/mL) for 48 h resulted in a significantly higher number of cells in the G 1 phase at the concentrations used: 20 µg/mL (47%, P<0.01) and 40 µg/mL (53%, P<0.01), compared with the non-berberine-treated control (36%; Figure 1B) . In each case, there was a concomitant reduction in the number of cells in the S and G 2 -M phases. These data suggested that the inhibition of cell proliferation in PG cells by berberine may be associated with the induction of G 1 arrest.
Berberine suppresses the cyclin D1 expression Based on the preliminary assays in which we determined the effects of berberine on cell proliferation and viability, in order to minimize the cytotoxic effect of berberine, we selected doses lower than 10 µg/mL for further mechanism studies.
Cyclin D1 is a downstream molecule regulated by the AP-1 and NF-κB signaling pathways, and is a key molecule that controls the cell cycle entry from the G 1 phase to the S phase. We applied RT-PCR and immunoblotting to check the mRNA and protein expressions of cyclin D1. Treatment with berberine at different concentrations significantly downregulated the cyclin D1 mRNA and protein expressions (Figure 2 ).
Berberine inhibits AP-1 transcriptional activity Luciferase activity in the cells with the AP-1 construct was significantly reduced by treatment with berberine at 2.5, 5, and 10 µg/mL, whereas luciferase activity in the cells containing the NF-κB construct showed no statistically significant changes in the presence of berberine ( Figure 3A, 3B ). After treatment with PMA (60 ng/mL) and ionomycin (1.25 µmol/L), the cells with the AP-1 construct showed a significant decrease in luciferase activity in the presence of berberine ( Figure 3C ). The results demonstrated that berberine could suppress the AP-1 pathway in PG cells, but had no significant effect on the NF-κB pathway, Moreover, berberine significantly inhibited the AP-1 pathway when it was activated by the stimulus.
Berberine inhibits the c-Jun expression
The luciferase assay results suggest that berberine inhibits the activity of the AP-1 pathway. c-Jun is primarily a positive regulator of cell proliferation [18] . The activated c-Jun-containing AP-1 complex induces the transcription of positive regulators of cell cycle progression, such as cyclin D1. We examined the effects of berberine on the expression of c-Jun by immunoblotting were treated with or without berberine. Whole-cell lysates were then prepared and subjected to SDS-PAGE followed by Western blotting with anti-c-Jun antibodies. Lanes 1-4, 0, 2.5, 5, and 10 µ g/mL berberine treated for 24 h. β-Actin was used as an internal loading control. Figure 2 . Effect of berberine on the expression of cyclin D1 in PG cells. (A) PG cells were treated with or without berberine. Total RNA was then isolated for the analysis of cyclin D1. Levels of mRNA were determined by RT-PCR. Lanes 1-3, 0, 2.5, and 5 µ g/mL berberine treated for 24 h. GAPDH was used as an internal loading control. (B) PG cells were treated with or without berberine or not. Wholecell lysates were then prepared and subjected to SDS-PAGE followed by Western blotting with anti-cyclin D1 antibodies. Lanes 1-4, 0, 2.5, 5, and 10 µ g/mL berberine treated for 24 h. β-Actin was used as an internal loading control. using the same culture and treatment conditions as before. Berberine treatment (2.5, 5, and 10 µg/mL) significantly decreased the expression of c-Jun ( Figure 3D ).
Berberine decreases transcription factors binding to the CCND1 gene AP-1 motif To validate the previous results further, EMSA were performed by using oligonucleotides containing the wild-type collagenase AP-1 site as the probe. The PG cells were incubated in the presence of different concentrations of berberine for 24 h, and nuclear extracts were then prepared and analyzed for AP-1 DNA binding activity. The results indicated that the activity of AP-1 decreased dramatically when the cells were treated with berberine ( Figure 4A ). These data were consistent with the reporter gene analysis. The binding of transcription factors to the CCND1 gene AP-1 motif was detected by using oligonucleotides containing the CCND1 AP-1 site as the probe.
The binding decreased in the presence of berberine, while the mute probes had no effect on the combination ( Figure  4B ). The results suggested that berberine blocked the cyclin D1 expression, at least in part, by decreasing the expression or DNA binding activity of members of the AP-1 transcription factor family.
Discussion
Berberine is one of the major components of Coptis chinensis, which was frequently used in proprietary herbal medicines to treat inflammation in Europe and Asia. Berberine exhibits a broad spectrum of antimicrobial activity by inhibiting fungal, yeast, and bacterial proliferation with no toxicity. Studies have shown that berberine exerts a wide range of effects on angiogenesis [19] , cell proliferation, apoptosis [20] , cell cycle [21] , and tumor metastasis in various in vivo and in vitro models. It is then valuable to investigate the mechanisms of such antitumoral effects of berberine.
The inhibitory effect of berberine on AP-1 activity has been reported previously [22, 23] . However, the action mechanism of berberine on AP-1 remains unknown. The downstream target genes of AP-1, containing putative AP-1-binding sites in the promoters, are involved in many critical cellular functions, such as cell cycle progression and DNA synthesis [18] . CCND1 is a prototype of such a gene that may directly link AP-1 to cell cycle progression. Cyclin D1 antisense treatment blocks mammary tumor growth in vivo [24] , and cyclin D1 knockout mice are resistant to mammary tumor development by ras [25, 26] . In the present study, we demonstrated that berberine inhibits the expression of cyclin D1 by downregulating AP-1 transcriptional activity. Thus berberine arrests cell cycle progression and exerts antitumoral effects.
In summary, our results show that berberine significantly suppresses AP-1 transcriptional activity, leading to the inhibition of the cyclin D1 expression through the suppression of the c-Jun expression and binding of transcription factors to the CCND1 gene AP-1 motif. Berberine arrests cell cycle progression and proliferation of PG cells. These findings elucidate one of the important mechanisms behind the antitumoral effects of berberine as a regulator of cyclin D1. 
